Identification of a PD1/PD-L1 inhibitor by Structure-Based Pharmacophore Modelling, Virtual Screening, Molecular docking and Biological Evaluation.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular informatics"
DOI: 10.1002/minf.202200254
Abstract: PD-1/PD-L1 is a critical druggable target for immunotherapy against sepsis. Chemoinformatics techniques involved the structure-based 3D pharmacophore model development followed by virtual screening of small molecule databases to identify the small molecules against PD-L1 pathway… read more here.
Keywords: identification pd1; virtual screening; based pharmacophore; pd1 inhibitor ... See more keywords
PD1 inhibitor in combination with 5-azacytidine and low-dose DLI for the successful treatment of AML patients who relapsed after transplantation
Sign Up to like & getrecommendations! Published in 2020 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-020-01130-8
Abstract: Acute myeloid leukaemia (AML) patients who relapse after allogeneic haematopoietic stem cell transplantation (allo-HSCT) have a poor prognosis. The management of AML relapse after allo-HSCT remains a major therapeutic challenge. Here, to the best of… read more here.
Keywords: inhibitor combination; pd1 inhibitor; successful treatment; aml patients ... See more keywords